Lung Cancer
Conference Coverage
Lung cancer screening, early diagnosis still lower among blacks, Hispanics
San Francisco – Even after implementation of National Comprehensive Cancer Network guidelines, blacks, Asians, and Hispanics less often receive...
News from the FDA/CDC
Lung cancer on the decline, but still higher among men than women
CDC stresses universal screening for smoking and other lung cancer risk factors.
Conference Coverage
Nivolumab benefit for NSCLC persists at 5-year follow-up
BARCELONA – Nivolumab, compared with docetaxel chemotherapy, led to a fivefold improvement in 5-year overall...
Conference Coverage
Robotic bronchoscopy beat standard techniques for targeting lung nodules
NEW ORLEANS – Robotic bronchoscopy targeted lung nodules more effectively than did electromagnetic navigation or an ultrathin bronchoscope with...
Conference Coverage
Fluoroscopic system can improve targeting of lung lesions
The system increased the percentage of cases in which the target overlapped with the lesion.
Conference Coverage
Immune checkpoint inhibition in SCLC: Modest outcomes, many questions
Immune checkpoint inhibitors have activity in SCLC, but achieving more durable disease control and better survival requires greater understanding...
Conference Coverage
Patients have good recall on lung cancer screening scan benefits, not risks
NEW ORLEANS – Results suggest need for ongoing patient education beyond the initial shared decision-making encounter.
From the Journals
Stereotactic body radiation therapy safe, effective for moderately central NSCLC
A stereotactic body radiation therapy regimen of 50 Gy given in five fractions had limited toxicity and yielded good survival in a cohort of...
Conference Coverage
Next-gen genomic test plus bronchoscopy may improve lung nodule management
NEW ORLEANS – The test is seen as complementary to bronchoscopy, improving the sensitivity of bronchoscopy.
Conference Coverage
Immunotherapy duo extends survival in first line for advanced NSCLC
BARCELONA – Nivolumab and low-dose ipilimumab improved survival of patients with untreated advanced non–small cell lung cancer regardless of PD-L1...